<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752035</url>
  </required_header>
  <id_info>
    <org_study_id>2215-CL-0201</org_study_id>
    <secondary_id>2015-001790-41</secondary_id>
    <nct_id>NCT02752035</nct_id>
  </id_info>
  <brief_title>A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy</brief_title>
  <official_title>A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study for adult patients who have recently been diagnosed with acute&#xD;
      myeloid leukemia or AML. AML is a type of cancer. It is when bone marrow makes white blood&#xD;
      cells that are not normal. These are called leukemia cells. Some patients with AML have a&#xD;
      mutation, or change, in the FLT3 gene. This gene helps leukemia cells make a protein called&#xD;
      FLT3. This protein causes the leukemia cells to grow faster.&#xD;
&#xD;
      For patients with AML who cannot receive standard chemotherapy, azacitidine (also known as&#xD;
      Vidaza®) is a current standard of care treatment option in the United States. This clinical&#xD;
      study is testing an experimental medicine called ASP2215, also known as gilteritinib.&#xD;
      Gilteritinib works by stopping the leukemia cells from making the FLT3 protein. This can help&#xD;
      stop the leukemia cells from growing faster.&#xD;
&#xD;
      This study will compare two different treatments. Patients are assigned to one of these two&#xD;
      groups by chance: a medicine called azacitidine, also known as Vidaza®, or an experimental&#xD;
      medicine gilteritinib in combination with azacitidine. There is a twice as much chance to&#xD;
      receive both medicines combined than azacitidine alone. The clinical study may help show&#xD;
      which treatment helps patients live longer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients considered an adult according to local regulation at the time of obtaining informed&#xD;
      consent may participate in the study.&#xD;
&#xD;
      Safety Cohort Prior to initiation of the randomized trial, 8 to 12 patients will be enrolled&#xD;
      to evaluate the safety and tolerability of ASP2215 given with azacitidine therapy in the&#xD;
      study population.&#xD;
&#xD;
      Randomized Trial Approximately 250 patients will be randomized in a 2:1 ratio to receive&#xD;
      ASP2215 plus azacitidine (Arm AC) or azacitidine only (Arm C). Patients will enter the&#xD;
      screening period up to 14 days prior to the start of treatment. Patients will be administered&#xD;
      treatment over 28-day cycles.&#xD;
&#xD;
      Earlier protocol versions included a 1:1:1 randomization ratio to receive Arm A: ASP2215, Arm&#xD;
      AC: ASP2215 + azacitidine or Arm C: azacitidine. Patients previously randomized to Arm A&#xD;
      should continue following treatment and assessments as outlined in the protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 77 months</time_frame>
    <description>OS is defined as the time from the date of randomization until the date of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>Up to 77 months</time_frame>
    <description>EFS is defined as the time from the date of randomization until the date of documented relapse from complete remission (CR), treatment failure or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Best response is defined as the best measured response (in the order of CR, CRp, Cri or treatment failure defined by lack of composite complete remission (CRc)) from all post-baseline visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR) rate</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Complete remission rate is defined as the number of patients with all complete CRs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite complete remission (CRc) rate</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>CRc rate is defined as the number of patients with all complete and incomplete CRs (i.e., CR + Complete remission with incomplete platelet recovery (CRp) + Complete remission with incomplete hematologic recovery (Cri)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission with partial hematologic recovery (CRh) rate</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>CRh rate is defined as the number of patients who achieve CRh at any of the post-baseline visits and do not have best response of CR divided by the number of patients in the analysis population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission and complete remission with partial hematological recovery (CR/CRh) rate</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>CR/CRh rate is defined as the number of patients who achieve either CR or CRh at any of the post-baseline visits divided by the number of patients in the analysis population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion conversion rate</measure>
    <time_frame>Up to 49 months</time_frame>
    <description>Transfusion conversion rate is defined as the number of patients who were transfusion dependent at the baseline period but become transfusion independent at the post-baseline period divided by the total number of patients who were transfusion dependent at baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion maintenance rate</measure>
    <time_frame>Up to 49 months</time_frame>
    <description>Transfusion maintenance rate is defined as the number of patients who were transfusion independent at the baseline period and still maintain transfusion independence at the post-baseline period divided by the number of patients who were transfusion independent at baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia free survival (LFS)</measure>
    <time_frame>Up to 77 months</time_frame>
    <description>LFS is defined as the time from the date of first composite complete remission (CRc) until the date of documented relapse or death for subjects who achieve CRc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Duration of remission includes duration of CRc, CR, Cri, CRp and response (CRc + partial response [PR]). Duration of CRc is defined as the time from the date of first CRc until the date of documented relapse for subjects who achieve CRc. Duration of remission is similarly defined for CR, Cri and CRp.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant reported fatigue from Brief Fatigue Inventory (BFI)</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>The BFI was developed to assess the severity of fatigue and the impact of fatigue on daily functioning in subjects with fatigue due to cancer and cancer treatment The BFI inventory has 9 items and a 24-hour recall. A global fatigue score is computed by averaging the 9 items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by adverse events (AEs)</measure>
    <time_frame>Up to 49 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal laboratory values and/or adverse events related to treatment</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal vital signs and/or adverse events related to treatment</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Physical Exam abnormalities and/or adverse events</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Number of participants with potentially clinically significant physical exam values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by electrocardiograms (ECGs)</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>The 12-lead ECGs will be recorded in triplicate (3 separate ECGs) and transmitted electronically for central reading. The mean of the triplicate ECG from central read will be used for all final treatment decisions and adverse event reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG) performance status score</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>ECOG performance status measured on 6 point scale to assess participant's performance status. 0=Fully active, able to carry on all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; 2= Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; 5=Dead. 0=Best status; 5=Worst status.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation</condition>
  <arm_group>
    <arm_group_label>Dose escalation of ASP2215 given with azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with ASP2215 daily (days 1-28) and azacitidine daily for 7 days (days 1-7).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A: ASP2215</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated daily each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm AC: ASP2215 + azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with ASP2215 daily and azacitidine daily for 7 days (days 1-7) each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: azacitidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be treated with azacitidine for 7 days (days 1-7) each 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gilteritinib</intervention_name>
    <description>Tablet, oral</description>
    <arm_group_label>Arm A: ASP2215</arm_group_label>
    <arm_group_label>Arm AC: ASP2215 + azacitidine</arm_group_label>
    <arm_group_label>Dose escalation of ASP2215 given with azacitidine</arm_group_label>
    <other_name>ASP2215</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
    <description>Subcutaneous injection or intravenous infusion</description>
    <arm_group_label>Arm AC: ASP2215 + azacitidine</arm_group_label>
    <arm_group_label>Arm C: azacitidine</arm_group_label>
    <arm_group_label>Dose escalation of ASP2215 given with azacitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is considered an adult according to local regulation at the time of obtaining&#xD;
             informed consent.&#xD;
&#xD;
          -  Subject has a diagnosis of previously-untreated AML according to World Health&#xD;
             Organization (WHO) classification [Swerdlow et al, 2008] as determined by pathology&#xD;
             review at the treating institution.&#xD;
&#xD;
          -  Subject is positive for FLT3 mutation (internal tandem duplication [ITD] or tyrosine&#xD;
             kinase domain [TKD] [D835/I836] mutation) (or for Korea only: ITD alone or ITD with&#xD;
             concurrent TKD activating mutation) in bone marrow or whole blood as determined by&#xD;
             central laboratory. Note: Only requirement of FLT3 mutation assessment by central&#xD;
             laboratory is only applicable to the randomization portion of the study.&#xD;
&#xD;
          -  Subject is ineligible for intensive induction chemotherapy by meeting at least 1 of&#xD;
             the following criteria:&#xD;
&#xD;
               -  Subject is ≥ 65 years of age and ineligible for intensive induction chemotherapy.&#xD;
&#xD;
               -  Subject is ≥ 18 to 64 years of age and has any of the following comorbidities:&#xD;
                  [Ex-US Only]: Congestive heart failure (New York Heart Association {NYHA} class ≤&#xD;
                  3) or ejection fraction (Ef) ≤ 50%; [US Only]: Severe cardiac disorder e.g.&#xD;
                  congestive heart failure (New York Heart Association [NYHA] class ≤ 3) requiring&#xD;
                  treatment, ejection fraction ≤ 50%, or chronic stable angina; [Ex-US Only]:&#xD;
                  Creatinine &gt; 2 mg/dL (177 µmol/L), dialysis or prior renal transplant; [US Only]:&#xD;
                  Creatinine clearance &lt; 45 mL/min; ECOG performance status ≥ 2;&#xD;
&#xD;
               -  [Ex-US Only]: Known pulmonary disease with decreased diffusion capacity of lung&#xD;
                  for carbon monoxide (DLCO) and/or requiring oxygen ≤ 2 liters per minute; [US&#xD;
                  Only] Severe pulmonary disorder (e.g., diffusion capacity of lung for carbon&#xD;
                  monoxide [DLCO] ≤ 65% or forced expiratory volume in the first second [FEV1] ≤&#xD;
                  65%); Prior or current malignancy that does not require concurrent treatment;&#xD;
                  Subject has received a cumulative anthracycline dose above 400 mg/m2 of&#xD;
                  doxorubicin (or cumulative maximum dose of another anthracycline). Any other&#xD;
                  comorbidity incompatible with intensive chemotherapy must be reviewed and&#xD;
                  approved by the Medical Monitor during screening and before randomization.&#xD;
&#xD;
          -  Subject must meet the following criteria as indicated on the clinical laboratory&#xD;
             tests:&#xD;
&#xD;
               -  Serum AST and ALT ≤ 3.0 x Institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5 x Institutional ULN&#xD;
&#xD;
               -  Serum potassium ≥ Institutional lower limit of normal (LLN)&#xD;
&#xD;
               -  Serum magnesium ≥ Institutional LLN Repletion of potassium and magnesium levels&#xD;
                  during the screening period is allowed.&#xD;
&#xD;
          -  Subject is suitable for oral administration of study drug.&#xD;
&#xD;
          -  Female subject is eligible to participate if female subject is not pregnant and at&#xD;
             least one of the following conditions applies:&#xD;
&#xD;
               -  Not a woman of childbearing potential (WOCBP); OR&#xD;
&#xD;
               -  WOCBP agrees to follow the contraceptive guidance starting at screening and&#xD;
                  continue throughout the study period, and for at least 180 days after the final&#xD;
                  study drug administration.&#xD;
&#xD;
          -  Female subject must agree not to breastfeed starting at screening and throughout the&#xD;
             study period, and for 60 days after the final study drug administration.&#xD;
&#xD;
          -  Female subject must not donate ova starting at screening and throughout the study&#xD;
             period, and for 180 days after the final study drug administration.&#xD;
&#xD;
          -  Male subject with female partners of childbearing potential must agree to use&#xD;
             contraception as detailed in Contraception Requirements, starting at screening and&#xD;
             continue throughout the study period, and for 120 days after the final study drug&#xD;
             administration.&#xD;
&#xD;
          -  Male subject must not donate sperm starting at screening and throughout the study&#xD;
             period and for 120 days after the final study drug administration.&#xD;
&#xD;
          -  Subject agrees not to participate in another interventional study while on treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject was diagnosed as acute promyelocytic leukemia (APL).&#xD;
&#xD;
          -  Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).&#xD;
&#xD;
          -  Subject has received previous therapy for AML, with the exception of the following:&#xD;
&#xD;
               -  Emergency leukapheresis&#xD;
&#xD;
               -  Hydroxyurea&#xD;
&#xD;
               -  Preemptive treatment with retinoic acid prior to exclusion of APL ≤ 7 days&#xD;
&#xD;
               -  Growth factor or cytokine support&#xD;
&#xD;
               -  Steroids&#xD;
&#xD;
          -  Subject has clinically active central nervous system leukemia.&#xD;
&#xD;
          -  Subject has been diagnosed with another malignancy that requires concurrent treatment&#xD;
             (with the exception of hormone therapy limited to those therapies that prevent&#xD;
             recurrence and/or spread of cancer) or hepatic malignancy regardless of need for&#xD;
             treatment.&#xD;
&#xD;
          -  Subject requires treatment with concomitant drugs that are strong inducers of&#xD;
             cytochrome P450 CYP3A/P-glycoprotein (P-gp).&#xD;
&#xD;
          -  Subject requires treatment with concomitant drugs that are strong inhibitors or&#xD;
             inducers of P-gp with the exception of drugs that are considered absolutely essential&#xD;
             for the care of the subject.&#xD;
&#xD;
          -  Subject requires treatment with concomitant drugs that target serotonin&#xD;
             5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the&#xD;
             exception of drugs that are considered absolutely essential for the care of the&#xD;
             subject.&#xD;
&#xD;
          -  Subject has congestive heart failure classified as New York Heart Association Class&#xD;
             IV.&#xD;
&#xD;
          -  Subject with mean Fridericia-corrected QT interval (QTcF) &gt; 480 ms at screening based&#xD;
             on central reading.&#xD;
&#xD;
          -  Subject with a history of Long QT Syndrome at screening.&#xD;
&#xD;
          -  [Ex-US Only]: Subject has known pulmonary function tests with diffusion capacity of&#xD;
             lung for carbon monoxide (DLCO) ≤ 50%, forced expiratory volume in the first second&#xD;
             (FEV1) ≤ 60%, dyspnea at rest or requiring oxygen or any pleural neoplasm (Transient&#xD;
             use of supplemental oxygen is allowed.)&#xD;
&#xD;
          -  Subject has active hepatitis B or C or other active hepatic disorder.&#xD;
&#xD;
               -  Subjects with positive hepatitis B surface antigen (HBsAg) or detectable&#xD;
                  hepatitis B DNA are not eligible.&#xD;
&#xD;
               -  Subjects with negative HBsAg, positive hepatitis B core antibody and negative&#xD;
                  hepatitis B surface antibody will be eligible if hepatitis B DNA is undetectable.&#xD;
&#xD;
               -  Subjects with antibodies to hepatitis C virus will be eligible if hepatitis C RNA&#xD;
                  is undetectable&#xD;
&#xD;
          -  Subject has any condition which makes the subject unsuitable for study participation,&#xD;
             including any contraindications of azacitidine.&#xD;
&#xD;
          -  Subject has a known or suspected hypersensitivity to ASP2215, azacitidine or any&#xD;
             components of the formulations used.&#xD;
&#xD;
          -  [US Only]: Subject is ≥ 65 to 74 years of age, suitable for and willing to receive&#xD;
             intensive induction chemotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-5975</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Cancer Center - Hematology/Oncology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center - John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Associates of Northern NJ</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College-New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHS Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>26615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61004</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61008</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>SA 5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61007</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32003</name>
      <address>
        <city>Bruxelles</city>
        <state>Bruxelles-Capitale, Region De</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32007</name>
      <address>
        <city>Brussel</city>
        <state>Bruxelles</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32006</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15009</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15011</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15002</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15006</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33003</name>
      <address>
        <city>Nimes Cedex 09</city>
        <state>Gard</state>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33002</name>
      <address>
        <city>Pessac</city>
        <state>Gironde</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33015</name>
      <address>
        <city>Rouen</city>
        <state>Haute-Normandie</state>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33019</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33018</name>
      <address>
        <city>Rennes</city>
        <state>Ille-et-Vilaine</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33001</name>
      <address>
        <city>Nantes cedex 01</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33023</name>
      <address>
        <city>Valenciennes</city>
        <state>Nord</state>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33013</name>
      <address>
        <city>Pierre-Benite</city>
        <state>Rhone</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33017</name>
      <address>
        <city>Le Mans</city>
        <state>Sarthe</state>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33012</name>
      <address>
        <city>Poitiers</city>
        <state>Vienne</state>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33009</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33020</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33004</name>
      <address>
        <city>Lille cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33006</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49002</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wurttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49007</name>
      <address>
        <city>Munchen</city>
        <state>Bayern</state>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49005</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49015</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49012</name>
      <address>
        <city>Braunschweig</city>
        <state>Niedersachsen</state>
        <zip>38118</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49004</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49009</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49003</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49011</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39009</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39015</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39012</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39004</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39007</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39001</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39014</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39006</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39005</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39011</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81018</name>
      <address>
        <city>Anjo</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81007</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81027</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81021</name>
      <address>
        <city>Fukuyama</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81031</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81033</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81015</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81034</name>
      <address>
        <city>Hitachi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81023</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81001</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81032</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81012</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81011</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81029</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81014</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81035</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81008</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81024</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81005</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81016</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81004</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81017</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81030</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81036</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81026</name>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81019</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82003</name>
      <address>
        <city>Namdong</city>
        <state>Incheon Gwang'yeogsiv</state>
        <zip>405 760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82013</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82006</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82002</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82001</name>
      <address>
        <city>Ulsan</city>
        <state>Ulsan Gwang'yeogsi</state>
        <zip>682-714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82014</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82010</name>
      <address>
        <city>Hwasun-gun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82015</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82012</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48003</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48004</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48002</name>
      <address>
        <city>Opole</city>
        <state>Opolskie</state>
        <zip>45-061</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48001</name>
      <address>
        <city>Olsztyn</city>
        <state>Warmińsko-mazurskie</state>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34003</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34007</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34008</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34004</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34010</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34009</name>
      <address>
        <city>Barcelona</city>
        <zip>8041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34002</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34013</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34005</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88604</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88605</name>
      <address>
        <city>Kwei Shan Hsiang</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88602</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88609</name>
      <address>
        <city>Tainan</city>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88601</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88608</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88610</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44007</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>ASP2215</keyword>
  <keyword>Newly Diagnosed AML</keyword>
  <keyword>gilteritinib</keyword>
  <keyword>Acute Myeloid Leukemia (AML)</keyword>
  <keyword>FLT3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

